For patients with locally advanced basal cell carcinoma (laBCC)
The only hedgehog pathway inhibitor with 2 years of response1
Objective Response Rate (ORR): 56% (n=37/66; 95% CI: 43-68). ORR=Complete Response (CR of 5%, n=3) + Partial Response (PR of 52%, n=34).1*
Median Duration of Response: 26.1 months (95% CI: 10.1 months, not reached).1
About the BOLT trial: A multicenter (58 centers, 12 countries), randomized, double-blind, phase II trial evaluating once-daily dosing of ODOMZO in 194 patients with laBCC. Patients were randomized 1:2 to the 200 mg or 800 mg dose.1,2
*All modalities used must have demonstrated absence of tumor to achieve a composite assessment of CR. PR is defined as ≥50% decrease in the sum of the product of perpendicular diameters (SPD) of the lesions by photo assessment and ≥30% decrease in the sum of diameters of lesions per MRI.1,2